CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

Riedinger, Jean-Marc; Wafflart, J.; Ricolleau, G.; Eche, N.; Larbre, Hélène; Basuyau, Jean-Pierre; Dalifard, I.; Hacène, K.; Pichon, M.

doi:10.1093/annonc/mdl120

Cited by 95 publications

(72 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CA-125 is also widely expressed in other tissues and is elevated in benign processes such as endometriosis, uterine leiomyomata, benign adnexal masses, tubal inflammation, liver disease, heart failure, menses, and pregnancy, limiting its utility in surveillance of ovarian cancer [19]. Finally, with a half-life estimated to range from 9-44 days [20], CA-125 cannot offer as rapid a response to tumor volume changes as ctDNA. On the other hand, while CT imaging is the standard approach in the evaluation of recurrence of disease, in our cohort there were six instances of negative CT imaging with detectable ctDNA in the face of residual disease.…”

Section: Discussionmentioning

confidence: 99%

Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers

Pereira

Vanegas

Anand

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers

Pereira

Vanegas

Anand

et al. 2016

Gynecologic Oncology

View full text Add to dashboard Cite

“…The most extensively studied marker for EOC is CA125 , Cooper et al 2002, Riedinger et al 2006, and determining its concentration in serum is essential for monitoring ovarian cancer progression. Fifty percent increase in serum CA125 level has been correlated to progression, and present progression definition of the Gynecological Cancer Intergroup defines progression based on two elevated serum CA125 levels.…”

Section: B Győ Rffy Et Al: Survival Analysis In Ovarian Cancermentioning

confidence: 99%

“…Despite extensive research, clinical-pathological factors including tumor stage, residual disease after surgery, histological type, and tumor grade are still the most important features related to patient outcome. To date, only two biomarkers have been approved by the Food and Drug Administration (FDA) for monitoring patients with EOC: CA125 (MUC16; Gadducci et al 1995, Cooper et al 2002, Riedinger et al 2006 and HE4 (WFDC2; Huhtinen et al 2009, Moore et al 2009.…”

Section: Introductionmentioning

confidence: 99%

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

Győrffy¹,

Lánczky²,

Szállási³

2012

Endocrine-Related Cancer

784

824

View full text Add to dashboard Cite

The validation of prognostic biomarkers in large independent patient cohorts is a major bottleneck in ovarian cancer research. We implemented an online tool to assess the prognostic value of the expression levels of all microarray-quantified genes in ovarian cancer patients. First, a database was set up using gene expression data and survival information of 1287 ovarian cancer patients downloaded from Gene Expression Omnibus and The Cancer Genome Atlas (Affymetrix HG-U133A, HG-U133A 2.0, and HG-U133 Plus 2.0 microarrays). After quality control and normalization, only probes present on all three Affymetrix platforms were retained (nZ22 277). To analyze the prognostic value of the selected gene, we divided the patients into two groups according to various quantile expressions of the gene. These groups were then compared using progression-free survival (nZ1090) or overall survival (nZ1287). A Kaplan-Meier survival plot was generated and significance was computed. The tool can be accessed online at www.kmplot. com/ovar. We used this integrative data analysis tool to validate the prognostic power of 37 biomarkers identified in the literature. Of these, CA125 (MUC16; PZ3.7!10 K5

show abstract

“…half-life and CA125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome (444 Osteopontin. Osteopontin was first identified by a cDNA microarray approach used to identify upregulated genes in ovarian cancer cells, and osteopontin has been found to be a potential diagnostic biomarker for ovarian cancer (468 ).…”

Section: Prognosismentioning

confidence: 99%

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

et al. 2008

View full text Add to dashboard Cite

Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed. Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed. Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer. Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

show abstract

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

Abstract: Among well-established prognostic factors in ovarian cancers, CA 125 half-life and nadir concentration bear a strong and independent prognostic value.

Cited by 95 publications

References 21 publications

Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers

Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers

Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

Contact Info

Product

Resources

About